News headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5556348983121 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have effected Accern’s analysis:

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down 3.29% during mid-day trading on Friday, hitting $14.72. The company had a trading volume of 273,558 shares. The stock’s market cap is $386.55 million. The stock’s 50-day moving average is $16.38 and its 200-day moving average is $16.38. Syros Pharmaceuticals has a 52-week low of $10.22 and a 52-week high of $17.89.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities analysts forecast that Syros Pharmaceuticals will post ($2.09) earnings per share for the current year.

A number of analysts recently issued reports on SYRS shares. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. JMP Securities raised Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price for the company in a research report on Thursday. Oppenheimer Holdings, Inc. set a $28.00 target price on Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 12th. Finally, Cann reissued a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $24.64.

ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals (SYRS) Receives Media Sentiment Rating of 0.22” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at

In other news, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.09, for a total transaction of $72,499.38. Following the completion of the transaction, the director now directly owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric R. Olson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the transaction, the insider now directly owns 2,500 shares of the company’s stock, valued at $58,975. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,564 shares of company stock valued at $476,803.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Insider Buying and Selling by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.